Exchange: NASDAQ·Updated 04:04 PM EDT

CSBR News

News
all
press releases
Champions Oncology Q4 2026 Earnings Call Transcript
On Monday, Champions Oncology (NASDAQ:CSBR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
Champions Oncology Q4 2026 Earnings Call Transcript
On Monday, Champions Oncology (NASDAQ:CSBR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
More News
Champions Oncology Q3 2026 Earnings Call Transcript
Champions Oncology (NASDAQ:CSBR) released third-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
Full Transcript: Champions Oncology Q1 2027 Earnings Call
On Thursday, Champions Oncology (NASDAQ:CSBR) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
Champions Oncology's first-quarter fiscal 2027 results record revenue and margin growth, stronger adjusted earnings and surging data-license revenues.
Zacks
Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Zacks
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
Zacks
2 Microcaps With Gross Margin Catalysts
CSBR and CEPL have levers in place for Gross Margin improvement.
Zacks
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.
Zacks
Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving Average - What's Next?
Champions Oncology (NASDAQ:CSBR) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened...
MarketBeat

Advertisement|Remove ads.